











Supplement Figure 1









AIsolation of Omenta from *SP*^{-/-} and *SP*^{+/+} mice**B****C****D****E****F**

Supplement Figure 2




Supplement Figure 3

SKOV3 SKOV3 SKOV3 SKOV3 SKOV3
 OVCAR3 OVCAR3 OVCAR3 OVCAR3 OVCAR3
 CAOV3 CAOV3 CAOV3 CAOV3 CAOV3




Supplement Figure 4




Supplement Figure 5


A









B




Supplement Figure 6




Supplement Figure 7












Supplement Figure 8:




Supplement Figure 9:



Supplement Figure 10:



Supplement Figure 11:



Supplement Figure 1: Patients' data of tumor tissue specimens.

A. WF-TTPSR (High Grade Serous):

	pT1+pT2	pT3+
Number	6	29
Age	61.5 ± 4.66	65.17 ± 2.113
Grade		
G1+G2	1	1
HG (G3+G4)	5	28

B. CHTN (serous papillary and poorly differentiated):

	pT1+pT2	pT3+
Number	10	30
Age	65.7 ± 5.916	63.2 ± 2.288
Grade:		
G1+G2	5	15
HG (G3+G4)	5	15

Supplement Table 2: Antibodies

Primary and secondary Antibodies	Catalog #	Dilution	Molecular weight
Rabbit Anti- SPARC (CST)	8725	1:250 (40 ug) WB 1:100 IHC (Paraffin and IF)	43 kDa
Mouse Anti-SPARC (Abnova) MAB0278	MAB0278	1:500 WB 1:100 IHC (Paraffin and IF)	43 kDa
Rabbit Anti- FABP4 (CST) Fatty acid binding protein	3544	1:1500 (25 ug) WB 1:200 IF	15 kDa
Rabbit Anti-CD36 (CST)	14347	1:200 IF	
Rabbit Anti- CEBP Alpha (CST) CCAAT/enhancer-binding proteins	8178	1: 1500 (25 ug) WB	42 kDa
Rabbit Anti- CEBP Beta (CST) CCAAT/enhancer-binding proteins	3084	1: 500 (25 ug) 1:200 IHC (Paraffin and IF)	38, 41 kDa
Rabbit Anti- PPAR Gamma (CST) Peroxisome proliferator-activated receptor	2435	1: 250 (25 ug)	53, 57 kDa
Rabbit Anti- HSL (Hormone Sensitive Lipase) (CST)	4139	1:3000 (25 ug)	81, 83 kDa
Rabbit- Anti- Phospho CEBP Thr 235 (CST)	3084	1:500	19 k Da LIP; 36-38 kDa LAP
Rabbit Anti- ATGL (CST)	2439	1:500	54 kDa
Mouse Anti- tubulin (Sigma)	T5168	1:5000	55 kDa
Anti-rabbit and anti-mouse HRP-conjugated antibodies (ThermoFisher)	Cat # 31460 Cat # 31430	1:2000 (WB) 1:400 (IHC-P)	
NIR680 and 800 anti-mouse and anti-rabbit secondary antibodies (Licor)	[P/N 925-32210] [P/N 925-32211] [P/N 925-68020] [P/N 925-68021]	1:10000 (WB)	
Alexa-fluor 488 anti-rabbit antibodies. (Invitrogen)	Cat # A-11034	1:400 (IF)	
Alexa-fluor 594 anti-rabbit antibodies. (Invitrogen)	Cat # A-11032	1:400 (IF)	

Supplementary Table 3: List of human primers used for real-time PCR

Gene	Forward Primer sequence [5'-3'] Oligo	Reverse Primer sequence [5'-3'] Oligo
GAPDH	AGGGCTGCTTTTAACTCTGGT	CCCCACTTGATTTTGGAGGGA
<i>IL6</i>	GGTACATCCTCGACGGCATCT	GTCCCTCTTTGCTGCTTTCAC
<i>CCL2</i>	CAGCCAGATGCAATCAATGC	GCACTGAGATCTTCCTATTGGTGAA
<i>VEGFA</i>	CTACCTCCACCATGCCAAGT	GCAGTAGCTGCGCTGATAGA
<i>TNFA</i>	GGAGAAGGGTGACCGACTCA	CTGCCCAGACTCGGCAA
<i>Leptin</i>	GAAGACCACATCCACACACG	AGCTCAGCCAGACCCATCTA

Supplementary Table 4: List of mouse primers used for real-time PCR

Gene	Forward Primer sequence [5'-3'] Oligo	Reverse Primer sequence [5'-3'] Oligo
<i>18S rRNA</i>	GTAACCCGTTGAACCCCAT	CCATCCAATCGGTAGTAGCG
<i>Cd36</i>	CCTTAAAGGAATCCCCGTGT	TGCATTTGCCAATGTCTAGC
<i>Gapdh</i>	CATTGTGGAAGGGCTCATGA	TCTTCTGGGTGGCAGTGATG
<i>Il-6</i>	AAAGAGTTGTGCAATGGCAATTCT	AAGTGCATCATCGTTGTTCATACA
<i>Ccl2</i>	GTTGGCTCAGCCAGATGCA	AGCCTACTCATTGGGATCATCTTG
<i>Vegfa</i>	CCTCCTCAGGGTTTCGGGAACCA	ACCCAAAGTGCTCCTCGAAGGATC
<i>Tnfa</i>	CATCTTCTCAA AATTCGAGTGACAA	TGGGAGTAGACAAGGTACAACCC
<i>Fabp4</i>	AAGGTGAAGAGCATCATAACCC	TCACGCCTTTCATAACACATTCC
<i>Pparg</i>	GGAAGACCACTCGCATTCCCTT	GTAATCAGCAACCATTGGGTCA
<i>Srebp-1c</i>	GATCAAAGAGGAGCCAGTGC	TAGATGGTGGCTGCTGAGTG
<i>Fasn</i>	AGAGATCCCGAGACGCTTCT	GCCTGGTAGGCATTCTGTAGT
<i>Scd1</i>	TTCTTACACGACCACCACCA	CCGAAGAGGCAGGTGTAGAG
<i>Hsl/Lipe</i>	TCTATGCGCAGGAGTGTGTC	TTGACATCAGAGGGTGTGGA
<i>Atgl</i>	CAACGCCACTCACATCTACGG	TCACCAGGTTGAAGGAGGGAT
<i>Acaca</i>	CTCCAGGACAGCACAGATCA	GCCGAAACATCTCTGGGATA
<i>Leptin</i>	CTCATGCCAGCACTCAAAAA	AGCACCACAAAACCTGATCC
<i>Adiponectin</i>	AGACCTGGCCACTTTCTCCT	ATCCAACCTGCACAAGTTCC
<i>Cebpa</i>	CAAGAACAGCAACGAGTACCG	GTCACTGGTCAACTCCAGCAC
<i>Cebpb</i>	ATCGACTTCAGCCCCTACCT	GGCTCACGTAACCGTAGTCG
<i>Cebpd</i>	CGACTTCAGCGCCTACATTGA	GAAGAGGTCGGCGAAGAGTT
<i>Acly</i>	CAGCCAAGGCAATTTAGAGC	CTCGACGTTTGATTA ACTGGTCT
<i>Acat1</i>	CTGGGCGCAGGTTTACCTAT	GGTGTGCTCCTCTGCTCAT
<i>Acat2</i>	ATTGTTGAAAGGTGGGCAGC	GGTAACATCCCATCCCGTCA
<i>Hadh</i>	TCGTGAACCGACTCTTGGTG	TCTTCCTTAGACGCATCGCC
<i>Crot</i>	ATTGGCTGGAAGAGTGGTGG	GAGTCCCTTCCTTTGGAGGC
<i>Acaa2</i>	GGGGCCTTCTCAAGGACTTC	ACATTGCCACGATGACACT
<i>Acaa1</i>	AGGCCCTCTAAAGACCCCAT	GGTGGGTCCTACCTACTCGT
<i>Cpt1a</i>	GGA CTCCGCTCGCTCATT	GAGATCGATGCCATCAGGGG
<i>Cpt1b</i>	CCTGGGATGCGTGTAGTGTT	CCTGGGATGCGTGTAGTGTT
<i>Slc25a20</i>	CATGTGCCTGGTGTGTTGTGG	GGTGGCTGTCCAGACAAACT

Supplement Figure Legends:

Supplement Figure 1: Isolation of primary mouse peritoneal stromal cells. **A.** Schema of the isolation of omental adipocytes from $SP^{-/-}$ and $SP^{+/+}$. **B.** Oil O red staining of freshly isolated primary adipocytes. **C.** α -smooth muscle actin (α -sma) staining showing fibroblastoid phenotype of omental stromal cells. **D.** Western blot showing the expression of SPARC protein in $SP^{-/-}$ and $SP^{+/+}$ adipocytes. **E.** Phase contrast (left), fluorescence (middle) and merged phase/fluorescent images of ID8-GFP cells showing the GFP expression levels. Scale bars, 100 μ m. **F.** Coomassie blue stained SDS-PAGE (4-20%) gel showing rhSPARC molecular weights at the indicated concentrations reconstituted in DPBS containing 0.1% BSA under reducing and non-reducing conditions. Five microliters of 0.1% BSA alongside the samples in lane 10.

Supplement Figure 2: Homing of Ovarian Cancer cells towards normal adipocytes is mediated through secreted factors. **A.** Bar graphs of the means \pm SEM of the levels of cytokines and chemokines secreted in CM of normal $SP^{+/+}$ and $SP^{-/-}$ adipocytes, $*p < 0.05$ comparing $SP^{+/+}$ and $SP^{-/-}$ adipocytes, Student's t -test. **B.** Bar graphs of the means \pm SEM of the relative fluorescence intensity of ID8-GFP that homed to $SP^{+/+}$ and $SP^{-/-}$ *in vivo* in the presence of functional blocking antibodies to the indicated chemokines and their isotype controls. $*p < 0.05$ comparing $SP^{+/+}$ and $SP^{-/-}$ within each condition; $^{\#}p < 0.05$ compared to isotype control. $^{\$}p < 0.05$ comparing the $SP^{-/-}$ to the corresponding isotype control. **C.** Bar graphs of the means \pm SEM of the levels of cytokines and chemokines secreted in CM of normal $SP^{+/+}$ and $SP^{-/-}$ CAA. $*p < 0.05$ comparing $SP^{+/+}$ and $SP^{-/-}$ adipocytes, Student's t -test. **D.** Schema of the homing/migration of ID8 cells towards normal Adi and CAA and their CM. Bars report mean \pm SEM of the fold increase in migration compared to control medium considered as 1. $*p < 0.05$ comparing $SP^{+/+}$ and $SP^{-/-}$. $**p < 0.05$ comparing normal Adi to CAA. $***p < 0.05$ comparing migration towards adipocytes to 72h CM.

Supplement Figure 3: Adipocyte-SPARC inhibits co-culture-induced activation of cEBP β , NF κ B and AP-1 in primary human omental adipocytes and human OvCa cells A. Schematic illustration of the experimental design of the co-cultures of OvCa cells and omental adipocytes. **B.** Primary human omental adipocytes overexpressing (hAdi-VC and hAdi-SPARC) or depleted of SPARC (hAdi-NTsh and hAdi-shSPARC) and their vector controls were transfected with luciferase reporter plasmids of cEBP β , NF κ B and AP-1 and were co-cultured with human OvCa cells for further 24h. The activation of each transcription factor was determined by measuring the luciferase reporter activity in each cell type. Bars represent mean

± SEM of one of three experiments performed in triplicates. * $p < 0.05$ comparing hAdi-NTsh and hAdi-shSPARC ** $p < 0.05$ comparing hAdi-VC and hAdi-SPARC; and # $p < 0.05$ student's *t*-test comparing cells in single to co-cultures; comparing OvCa cells in single to co-culture with hAdi-VC and hAdi-SPARC; Student's *t*-test **C**. Treatment of mono- and co-cultures of OvCa cells and adipocytes with rSPARC (5µg/ml). The activation of each transcription factor was determined by measuring the luciferase reporter activity in each cell type. Bars represent mean ± SEM of one of three experiments performed in triplicates. * $p < 0.05$ comparing cells with/without rSPARC; # $p < 0.05$ student's *t*-test comparing cells in single to co-cultures.

Supplement Figure 4: The proliferation of the OvCa cell lines in mono and co-cultures with adipocytes (under same experimental conditions of luciferase reporter assays **Figure 3C** and **Supplement Figure 3B-C**) was determined by CyQuant assay at the start of the experiments with mono- and co-cultures (0h) and at the end of the experiment (24h). Fold changes of the DNA content (proliferation) was determined for each cell type at 0 and 24h. Bars represent mean ± SEM of fold change in proliferation measured at 24h over 0h at the start of co-culture. *p* values were determined by unpaired Student's *t*-test. These fold changes were used to correct for the luciferase activity levels presented in **Figure 3C** and **Supplement Figure 3B-C**.

Supplement Figure 5: Exogenous rSPARC suppresses co-culture-induced activation of cEBPβ, NFκB and AP-1 in primary human omental adipocytes and human OvCa cells. **A.** the expression of the transcripts of IL-6, CCL2, Leptin, VEGF, and TNFα was determined in human OvCa cells in single and co-cultures with primary human adipocytes (hAdi) as described in **Supplement Figure 3**. Bars represent mean ± SEM of the fold changes in the transcript in ID8 cells in co-cultures compared to single cultures considered as 1 in one of three experiments performed in triplicates. **B.** Bars represent the mean ± SEM of the fold changes in the transcript levels in adipocytes in co-cultures compared to single cultures considered as 1. * $p < 0.05$, unpaired Student's *t*-test.

Supplement Figure 6: A. H&E sections of omental metastasis of HGSC specimens at indicated magnifications. **B.** Immunofluorescence showing the expression of SPARC in tumor cells (T) and adipocytes (A).

Supplement Figure 7: Effect of blockade of NFκB, AP-1 and cEBPβ on their activity in OvCa cells and adipocyte: Treatment of ID8 and adipocytes in single and co-cultures with NFκB cell permeable peptides S276 pep and NLS pep inhibited NFκB and cEBP luciferase

reporters in adipocytes **A-B**, and ID8 cells, **C-D**. * $p < 0.05$ between controls and inhibitor treatments, ** $p < 0.05$ comparing $SP^{+/+}$ and $SP^{-/-}$ adipocytes. *** $p < 0.05$ comparing cells in mono- and co-cultures. **E**. Treatment of ID8 and adipocytes in single and co-cultures with JNK inhibitor SP600125 inhibited co-culture induced AP-1 luciferase reporter in both cell types. * $p < 0.05$ comparing controls with inhibitor treatments. Bars represent mean \pm SEM of one of 2 experiments each performed in quadruplicates. ** $p < 0.05$ comparing $SP^{+/+}$ and $SP^{-/-}$ adipocytes. § $p < 0.05$ comparing adipocytes in mono- and co-cultures with ID8 cells, # $p < 0.05$ comparing ID8 in mono can co-cultures with adipocytes; unpaired Student's *t*-test. **F**. The proliferation of the ID8 cells in mono and co-cultures with $SP^{+/+}$ and $SP^{-/-}$ adipocytes (under same experimental conditions of luciferase reporter assays in **A-E** was determined by CyQuant assay at the start of the experiments with mono- and co-cultures (0h) and at the end of the experiment (24h). Fold changes of the DNA content (proliferation) was determined for each cell type at 0 and 24h. Bars represent mean \pm SEM of fold change in proliferation measured at 24h over 0h at the start of co-culture. * $p < 0.05$ compared to control ID8 cells in mono-cultures. # $p < 0.05$, comparing ID8 cells in coculture with $SP^{+/+}$ and $SP^{-/-}$ adipocytes, unpaired Student's *t*-test. These fold changes were used to correct for the luciferase activity levels presented in **A-E**.

Supplement Figure 8: Inhibition of NF κ B (S276 and NLS peptides) and AP-1 (JNK inhibitor, SP6000125) inhibited co-culture-induced FFA release from adipocytes in mono and co-cultures with ID8 cells. Bars represent means \pm SEM fluorescent intensity of the released of FFA from a representative of 3 independent experiments each preformed in quadruplicates. * $p < 0.05$ comparing controls with inhibitor treatments, ** $p < 0.05$ comparing $SP^{+/+}$ and $SP^{-/-}$ adipocytes, *** $p < 0.05$ comparing mono- and co-cultures; Student's *t*-test.

Supplement Figure 9: Effect of SPARC on adipogenic differentiation factors in 3T3L1 adipocytes. 3T3L pre-adipocytes were stimulated to differentiate into adipocytes the presence with the appropriate media as described in "Material and Methods" in the presence or absence of 5 μ g/ml recombinant murine SPARC. mRNA was isolated at the indicated time points. Bars report means \pm SEM of the expression levels of the indicated genes of a representative of 2 experiments each performed in triplicates. * $p < 0.05$, Student's *t*-test.

Supplement Figure 10: Bars depict means \pm SEM of lipid metabolites measured in ID8 omental tumor nodules isolated 6 weeks after ip injection of ID8 in $SP^{+/+}$ and $SP^{-/-}$ mice (n=6/genotype). $p < 0.05$, Student's *t*-test.

Supplement Figure 11: Kaplan Meier curves curated from TCGA and Protein Atlas (<https://www.proteinatlas.org/>) showing the correlation of the expression of cEBP β , AP-1 (cJun and cFos) and NF κ B (RelA, and NF κ B1) and downstream target inflammatory and metabolic genes with patients' survival. * $p < 0.05$.